Sinnathurai Premarani, Lau Wendy, Vieira de Ribeiro Ana Julia, Bachovchin William W, Englert Helen, Howe Graydon, Spencer David, Manolios Nicholas, Gorrell Mark D
Rheumatology Department, Westmead Hospital, Westmead, New South Wales, Australia.
Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
Int J Rheum Dis. 2018 Nov;21(11):1915-1923. doi: 10.1111/1756-185X.13031. Epub 2016 Dec 19.
To quantify circulating fibroblast activation protein (cFAP) and dipeptidyl peptidase 4 (cDPP4) protease activities in patients with rheumatoid arthritis (RA), systemic sclerosis (SSc), and a control group with mechanical back pain and to correlate plasma levels with disease characteristics.
Plasma was collected from patients with RA (n = 73), SSc (n = 37) and control subjects (n = 26). DPP4 and FAP were quantified using specific enzyme activity assays.
Median cDPP4 was significantly lower in the RA group (P = 0.02), and SSc group (P = 0.002) compared with controls. There were no significant differences in median cFAP between the three groups. DPP4 and FAP demonstrated a negative correlation with inflammatory markers and duration of disease. There were no associations with disease subtypes in RA, including seropositive and erosive disease. Decreased cDPP4 was found in SSc patients with myositis. Plasma FAP was lower in RA patients receiving prednisone (P = 0.001) or leflunomide (P = 0.04), but higher with biologic agents (P = 0.01). RA patients receiving leflunomide also had decreased cDPP4 (P = 0.014). SSc patients receiving prednisone (P = 0.02) had lower cDPP4 but there was no association with cFAP.
No association was found between cFAP and RA or SSc. Plasma DPP4 was decreased in RA and SSc when compared with controls. cDPP4 and cFAP correlated negatively with inflammatory markers and there were no significant correlations with disease characteristics in this RA cohort.
对类风湿关节炎（RA）、系统性硬化症（SSc）患者以及机械性背痛对照组患者的循环成纤维细胞活化蛋白（cFAP）和二肽基肽酶4（cDPP4）蛋白酶活性进行定量，并将血浆水平与疾病特征相关联。
收集RA患者（n = 73）、SSc患者（n = 37）和对照受试者（n = 26）的血浆。使用特定酶活性测定法对DPP4和FAP进行定量。
与对照组相比，RA组（P = 0.02）和SSc组（P = 0.002）的cDPP4中位数显著更低。三组之间的cFAP中位数无显著差异。DPP4和FAP与炎症标志物及疾病持续时间呈负相关。在RA中，与疾病亚型（包括血清阳性和侵蚀性疾病）无关联。在合并肌炎的SSc患者中发现cDPP4降低。接受泼尼松（P = 0.001）或来氟米特（P = 0.04）治疗的RA患者血浆FAP较低，但使用生物制剂时更高（P = 0.01）。接受来氟米特治疗的RA患者cDPP4也降低（P = 0.014）。接受泼尼松治疗的SSc患者（P = 0.02）cDPP4较低，但与cFAP无关联。
未发现cFAP与RA或SSc之间存在关联。与对照组相比，RA和SSc患者的血浆DPP4降低。在该RA队列中，cDPP4和cFAP与炎症标志物呈负相关，与疾病特征无显著相关性。
